2016年6月30日博士毕业于华南农业大学园艺学院。2016年3月至2017年2月，担任中国科学院植物生理生态研究所研究助理。2017年3月至2017年9月，担任复旦大学生命科学学院研究助理。2017年10月至2021年2月，担任复旦大学博士后和佛罗里达大学研究助理。2021年3月至2022年9月，担任佛罗里达大学博士后。2022年10月至2024年3月，担任佛罗里达大学高级科学家。2024年8月加入合肥综合性国家科学中心大健康研究院金腾川课题组，从事病毒学、基因治疗、肿瘤学和免疫学研究。发表10余篇SCI期刊文献，1本专业学术论著。申请1项国家自然基金项目，1项地方自然基金项目，1项博士后基金项目。担任Cancer Treatment and Survivorship, Precision Oncology的学术著作编辑。担任Annals of Urology, The European Journal of Cancer, The Journal of Clinical Microbiology, The Journal of Hypertension, Molecular & Cellular Biomechanics, Frontiers in Immunology, Global Translational Medicine的学术期刊编辑。担任Current Advances in Medicine, International Journal of Clinical and Surgical Pathology, International Journal of Clinical Case Reports and Reviews, Oncogen, Mathews Journal of Cancer Science, Advancements in Journal of Urology and Nephrology, American Journal of Biomedical Science & Research的学术编委成员。担任14th World Gene Convention European Branch, 11th World Congress on Cancer Research and Therapy, 3rd International Conference on Innovations and Advances in Cancer Research and Treatment的大会组委会成员.  担任国际科学与工程大奖Plant Sciences, Animal Sciences, Microbiology, Biomedical and Health Sciences的专业领域评审。获得Global Recognition Awards。

1. 肿瘤发病机制的阐明

2. 肿瘤生物标志物的发掘

3. 肿瘤递送载体的筛选

4. 肿瘤疫苗的开发

5. 肿瘤临床数据库的建立

1. Ling Yin, Chapter "Gene Editing in ErbB/HER Family-Mediated Cancer Immunology", IntechOpen book "Genome Editing - Recent Advances and Applications", 2025.

2. Ling Yin. Using gene therapy to circumvent limitations of TRAIL-based cancer therapy. Mol Ther Oncol. 2024. 32:200844.

3. Ling Yin. Combination Therapy of Bevacizumab and Galunisertib Extend TVN Time Window. Mol Ther Oncol. 2024. 32: 200888.

4. Ping Zhu, Frank Dyka, Xiaojie Ma, Ling Yin co-first author, Heather Yu, Wolfgang Baehr, William W. Hauswirth, Wen-Tao Deng. Disease mechanisms of X-linked cone dystrophy caused by missense mutations in the red and green cone opsins. FASEB J, 2021. 35:e21927.

5. Ling Yin, Geoffrey D. Keeler, Yuanhui Zhang, Brad E. Hoffman, Chen Ling, Keyun Qing, Arun Srivastava. AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo. Gene Therapy, 2021. 28:422–434.

6. Hua Yang, Keyun Qing, Geoffrey D Keeler, Ling Yin, Mario Mietzsch, Chen Ling, Brad E Hoffman, Mavis Agbandje-McKenna, Mengqun Tan, Wei Wang, Arun Srivastava. Enhanced transduction of human hematopoietic stem cells by AAV6 vectors: Implications in gene therapy and genome editing. Molecular Therapy - Nucleic Acids, 2020. 20:451-458.

7. Ling Yin, Bihao Cao, Hancai Chen, Jianjun Lei, Guoju Chen. Molecular characterization and expression analysis of MYB28 involved in aliphatic glucosinolate biosynthesis in Chinese kale Brassica oleracea var. alboglabra Bailey. Frontiers in Plant Science, 2017. 8:1083.

8. Ling Yin, Changming Chen, Guoju Chen, Bihao Cao, Jianjun Lei. Molecular cloning, expression pattern and genotypic effects on glucoraphanin biosynthetic related genes in Chinese kale Brassica oleracea var. alboglabra Bailey. Molecules, 2015. 20:20254-20267.